文献速递慢性肾脏病肾小球疾病肾血管病与高血压

慢性肾脏病患者中SGLT2抑制剂的处方:适应症扩展与实践考虑

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.
PubMed 文献 · Kidney Int Rep · 2022-05-05

SGLT2抑制剂是延缓慢性肾脏病进展的关键疾病修饰疗法,通过管球反馈降低肾小球高压,独立于血糖控制。本文综述其在糖尿病肾病与非糖尿病肾病患者中的当前适应症,包括心衰、4期CKD和慢性肾小球肾炎的新证据,并讨论处方实践考虑如eGFR急性下降、起始剂量、容量状态和不良事件缓解。

要点

  • SGLT2抑制剂通过降低肾小球高压延缓CKD进展,独立于降糖作用
  • EMPA-KIDNEY试验因疗效提前终止,提示SGLT2抑制剂可能不久适用于无白蛋白尿的CKD患者
  • 处方时需考虑起始eGFR急性下降、使用临床试验最低剂量、容量状态和不良事件缓解

核心结论

  • SGLT2抑制剂是预防CKD进展的关键疾病修饰疗法,其适应症已从糖尿病扩展至心衰、4期CKD和慢性肾小球肾炎等。

研究设计与样本

  • 综述,纳入SGLT2抑制剂在伴或不伴糖尿病肾病的CKD患者中的当前适应症及相关临床试验证据。

主要发现

  • SGLT2抑制剂通过管球反馈降低肾小球高压,独立于血糖控制延缓肾功能下降。
  • EMPA-KIDNEY试验因疗效提前终止,提示SGLT2抑制剂可能不久适用于无白蛋白尿的CKD患者。
  • 在糖尿病患者中,可考虑联合GLP-1受体激动剂、新型盐皮质激素受体拮抗剂或选择性内皮素受体拮抗剂以减少残余白蛋白尿和心血管风险。

关键数值与推荐

  • 起始SGLT2抑制剂时预期出现eGFR急性下降;应使用临床试验中的最低剂量;需考虑容量状态和不良事件缓解。

临床怎么用

  • 在伴或不伴糖尿病的CKD患者中处方SGLT2抑制剂时,应预期eGFR急性下降、使用临床试验最低剂量、评估容量状态并采取不良事件缓解措施。
  • 糖尿病患者可考虑联合GLP-1受体激动剂、新型盐皮质激素受体拮抗剂或选择性内皮素受体拮抗剂以减少残余白蛋白尿和心血管风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the progression of chronic kidney disease (CKD). These agents prevent decline in kidney function through reduction in glomerular hypertension mediated through tubuloglomerular feedback independent of their effect on glycemic control. The proliferation of clinical trials on SGLT2 inhibitors has rapidly expanded the approved clinical indications for these agents beyond patients with diabetes mellitus (DM). We review the current indications for SGLT2 inhibitors in patients with and without diabetic kidney disease, including new evidence for use in patients with heart failure with or without reduced ejection fraction, stage 4 CKD, and chronic glomerulonephritis. The EMPA-KIDNEY trial was recently stopped early for efficacy suggesting that SGLT2 inhibitors may soon be indicated for patients with CKD without albuminuria. We review practical considerations for prescription of SGLT2 inhibitors, including the anticipated acute decline in estimated glomerular filtration rate (eGFR) on initiation, initiating the lowest dosage used in clinical trials, volume status considerations, and adverse event mitigation. Combination therapy in patients with DM may be considered with agents, including glucagon-like peptide-1 receptor agonists (GLP-1-RAs), novel mineralocorticoid receptor antagonists, and selective endothelin receptor antagonists to reduce residual albuminuria and cardiovascular risk.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Yau K, Dharia A, Alrowiyti I, et al. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int Rep. 2022. PMID: 35812300. doi:10.1016/j.ekir.2022.04.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。